Latest Commentary

You're so fierce: A call for nominations of the top women in med tech

FierceMedicalDevices is putting together a list of the "Top 10 Women in Med Tech" for the very first time this year to honor top innovators, dealmakers and other standouts in the sector. And we have opened our online form for nominating women for this year's feature. Submit your nominations here.

Device share of healthcare venture capital funding hits decade low

While medical device venture activity may have picked up this year, the comparison point in 2013 was abysmally low. In addition, Series A device investment was still shrinking. That's according to a new report from Silicon Valley Bank. These trends are pushing the sector to be more reliant on angel investors, which are becoming more accessible with the advent of crowdfunding, and corporate VCs, who are stealthy but increasingly active.

Antibiotics, lab safety and disease outbreaks top CDC Director Tom Frieden's to-do list

I caught up with Dr. Tom Frieden, director of the U.S. Centers for Disease Control and Prevention, last week, prior to his address at the National Press Club in downtown Washington, DC. Other media outlets joined in later. Here are some takeaways from his speech on antibiotic resistance, as well as our conversation.

The Fiercest 15 in med tech: send us your best bets

Last year's Fierce 15 med tech winners include an implant maker for sinusitus that recently filed for an $80 million IPO, a fierce competitor to device giants Medtronic and Edwards Lifesciences in the emerging market for minimally invasive heart valves and a market leader in developing nerve-stimulating implant for rheumatoid arthritis and Crohn's disease. What will 2014 bring? That depends on you.

Devicemakers celebrate early regulatory wins despite 2013 setbacks

A slump in FDA premarket approvals in 2013 set a somber tone for the coming year. As EP Vantage reported in its "MedTech 2013 in Review," the agency's PMA approval rates were down 44% in 2013 from 2012, with only 23 approvals compared to 41 the previous year. Medical device makers are still struggling to bring their products to market, but a few companies celebrated big regulatory wins in 2014.

My sister, and life science's limits

On a cold January morning in 2013, my big sister, Gretchen, took her last, labored breath and died. She was 46. Over the course of her last month alive, I developed a growing sense of anger and desperation at how her doctors, as well as the drug and diagnostics industries, seemed to have failed her.

The top companies in med tech: 2013 revenue results

In 2013, a number of outside forces hammered the med tech industry. While things could have been better, most of the top 10 companies in the sector still enjoyed moderate year-over-year revenue gains.

The pacemaker inside me: What I learned about the industry as a cardiac patient

On Jan. 2, 2014, a pacemaker was implanted under my right clavicle, with two wire leads snaked through two veins and into my heart. My experience as a patient showed me how limited the true choices are for most U.S. cardiac patients, despite the marketing hype around innovation in the industry.

JPM 2014: GlySure CEO hits SF to advance ICU glucose monitoring device

Christopher Jones flew in from the U.K. to San Francisco on Jan. 10 to get a head start on celebrating milestones and networking. But the 2014 JPMorgan Healthcare Conference, which began on Jan. 13, was high on his agenda.

PureTech's Tal Medical faces a clinical test of its rapid depression treatment

Patients have a number of treatment options for depression in both the device and drug realms, but they can take days or weeks to work. Boston's Tal Medical is developing something it claims can do the job far more quickly: a noninvasive neuromodulation treatment that appears to boost a patient's mood in about 20-30 minutes.